INHIBIGEN

Genocea Biosciences, Inc.

Application Filed: 2020-02-14

Trademark Application Details

Mark For: INHIBIGEN® trademark registration is intended to cover the categories of vaccines, immunotherapies, immunogenic compositions, and cell therapies. [all]

Status

2020-02-18 UTC

LIVE APPLICATION Awaiting Examination

The trademark application has been accepted by the Office (has met the minimum filing requirements) and has not yet been assigned to an examiner.

Research	OneLook Acronym Finder
Serial Number	88797352
Registration Number	6398491
Mark Literal Elements	INHIBIGEN
Mark Drawing Type	4 - STANDARD CHARACTER MARK
Mark Type	SERVICE MARK
Register	May 14, 2021
Current Location	NEW APPLICATION PROCESSING 2020-02-18
Basis	1(b)
Class Status	ACTIVE
Primary US Classes	006: Chemicals and Chemical Compositions 018: Medicines and Pharmaceutical Preparations 044: Dental, Medical and Surgical Appliances 046: Foods and Ingredients of Foods 051: Cosmetics and Toilet Preparations 052: Detergents and Soaps
Primary International Class	005 - Primary Class (Pharmaceuticals) Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
Filed Use	No
Current Use	No
Intent To Use	Yes
Filed ITU	Yes
44D Filed	No
44E Current	No
66A Current	No
Current Basis	No
No Basis	No
Attorney Name	Douglas R. Wolf
Attorney Docket Number	G07842000300

Timeline

2020-02-14	Application Filed
2020-02-18	Location: NEW APPLICATION PROCESSING
2020-02-18	Status: Live/Pending
2020-02-18	Status: New application will be assigned to an examining attorney approximately 3 months after filing date.
2020-02-18	Transaction Date
2021-06-22	Trademark Registered

Trademark Parties (Applicants & Owners)

Party:	Genocea Biosciences, Inc.
Address	100 Acorn Park Drive Cambridge, MASSACHUSETTS UNITED STATES 02140
Legal Entity Type	Corporation
Legal Entity State	DELAWARE

Documents

Drawing	JPEG	2020-02-14
TEAS RF New Application	MULTI	2020-02-14
XSearch Search Summary	XML	2020-05-06
Offc Action Outgoing	MULTI	2020-05-13
Response to Office Action	MULTI	2020-11-12
Amendment and Mail Process Complete	MULTI	2020-11-14
Offc Action Outgoing	MULTI	2020-11-16
Amended Drawing	JPEG	2021-05-14
Amendment to Allege Use	MULTI	2021-05-14
Drawing	JPEG	2021-05-14
Specimen	JPEG	2021-05-14
TEAS Request Reconsideration after FOA	MULTI	2021-05-14
AAU Processing Complete	MULTI	2021-05-18
Amendment and Mail Process Complete	MULTI	2021-05-18
Notice of Acceptance of AAU	XML	2021-05-18
TRAM Snapshot of App at Pub for Oppostn	MULTI	2021-05-18
Publication & Issue Review Complete	MULTI	2021-05-19
Registration Certificate	PDF	2021-06-22

Attorney of Record

DOUGLAS R. WOLF
WOLF, GREENFIELD & SACKS, P.C.
600 ATLANTIC AVENUE
BOSTON, MA 02210

Good, Services, and Codes

IC 044. US 100 101. G & S: medical treatment of cancer, infectious diseases, immune system-related diseases and disorders, and pathogen-induced diseases and disorders, namely, immunotherapies; antigen-directed cell therapy services. FIRST USE: 20200512. FIRST USE IN COMMERCE: 20200512

International Codes:	5
U.S. Codes:	006,018,044,046,051,052
International Codes:	44
U.S. Codes:	100,101

Type Code	Type
GS0051	vaccines, immunotherapies, immunogenic compositions, and cell therapies
GS0441	medical treatment of cancer, infectious diseases, immune system-related diseases and disorders, and pathogen-induced diseases and disorders, namely, immunotherapies; antigen-directed cell therapy services

Trademark Filing History

Description	Date	Proceeding Number
REGISTERED-SUPPLEMENTAL REGISTER	2021-06-22
NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED	2021-05-18
LAW OFFICE PUBLICATION REVIEW COMPLETED	2021-05-18	66179
ASSIGNED TO LIE	2021-05-18	66179
USE AMENDMENT ACCEPTED	2021-05-17	94656
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER	2021-05-17
USE AMENDMENT FILED	2021-05-15	88889
TEAS/EMAIL CORRESPONDENCE ENTERED	2021-05-15	88889
AMENDMENT TO USE PROCESSING COMPLETE	2021-05-15	88889
TEAS REQUEST FOR RECONSIDERATION RECEIVED	2021-05-14
TEAS AMENDMENT OF USE RECEIVED	2021-05-14
CORRESPONDENCE RECEIVED IN LAW OFFICE	2021-05-14	88889
NOTIFICATION OF FINAL REFUSAL EMAILED	2020-11-16
FINAL REFUSAL WRITTEN	2020-11-16	94656
FINAL REFUSAL E-MAILED	2020-11-16
TEAS/EMAIL CORRESPONDENCE ENTERED	2020-11-13	88889
TEAS RESPONSE TO OFFICE ACTION RECEIVED	2020-11-12
CORRESPONDENCE RECEIVED IN LAW OFFICE	2020-11-12	88889
NOTIFICATION OF NON-FINAL ACTION E-MAILED	2020-05-13	6325
NON-FINAL ACTION WRITTEN	2020-05-13	94656
NON-FINAL ACTION E-MAILED	2020-05-13	6325
ASSIGNED TO EXAMINER	2020-05-06	94656
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM	2020-02-20
NEW APPLICATION ENTERED IN TRAM	2020-02-18

Similar Marks

Mark Image Registration \| Serial	Company Trademark Application Date
INHIBIGEN 88797352 not registered Live/Pending	Genocea Biosciences, Inc. 2020-02-14
INHIBIGEN 86766246 4959940 Live/Registered	Oxoid Limited 2015-09-23
INHIBIGEN 78917718 3545368 Dead/Cancelled	Oxoid Limited 2006-06-27

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.